Project Summary

CVXL-0255 Project is based on original small molecules, selective inhibitors of two kinases, Syk and JAk3, key players in the biological processes governing immuno-inflammatory diseases, as drugs for:

  • The treatment of atopic dermatitis, in both human and animal health,
  • The treatment of asthma, in inhaled form,
  • The treatment of chronic osteoarticular diseases (polyarthritis…), as a result of therapies based on biological molecules that inhibit cytokines.

CPh-1012, one of the most advanced chemical leads, has been shown in recognized preclinical models of atopic dermatitis in dogs. It is the subject of a development agreement in the field of animal health.

The chemical modulation of the already known structures makes it possible to envisage developments in other indications, benefiting from the knowledge acquired with CPh-1012.

Context and therapeutic objectives

The SYK protein kinase is involved in the biology of mast cells, basophils and eosinophils, that are strongly involved in allergic reactions. SYK is also involved in the biology of B lymphocytes, which produce antibodies against the host in autoimmune diseases, and which can also proliferate aberrantly and cause certain lymphomas. A SYK inhibitor therefore has therapeutic potential in allergic diseases such as atopic dermatitis or asthma, or in certain lymphomas. 

The protein kinases JAK3 and TYK2 belong to the family of Janus Kinases (JAK) and are involved in the signaling of several cytokines involved in inflammatory, allergic or autoimmune diseases. Inhibition of these kinases has been shown to have a beneficial effect on immune-mediated inflammatory diseases such as rheumatoid arthritis or inflammatory bowel diseases.

By targeting its three kinases, the molecules developed in CVXL-0255 project have major therapeutic potential in a wide range of immune system diseases. The selectivity of the product also makes it possible to anticipate a better safety of use compared to other kinase inhibitors, targeting only Syk or one or more kinases of the JAK family.

© 2024 CleveXel Pharma

Up ↑